🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Erlangen
Clinical trial register · Germany

Clinical Trials in Erlangen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Erlangen-Nürnberg Medical School41 AstraZeneca26 AbbVie17 Hoffmann-La Roche12 Merck Sharp & Dohme LLC12
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Erlangen

362 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562Systemic Sclerosis
DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Berlin, Cologne, Erlangen, Leipzig, München, Tübingen, Würzburg
2027-02-03
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
DrugNerandomilast
Boehringer Ingelheim
Phase 3
270
Bad Bramstedt, Berlin, Cologne, Erlangen, Freiburg im Breisgau, Halle, Jena, Kirchheim unter Teck
2026-11-09
Not yet open
ESR1Real World Assessment Prevalence Study
NCT07817212HR+/HER2- aBC Undergoing 1L Treatment With CDK4/6i (Palbociclib, Abemaciclib or Ribociclib) and AI (Anastrozole or Letrozole)
Institut fuer Frauengesundheit
Not applicable
1,550
Ansbach, Bremen, Celle, Dresden, Düsseldorf, Erlangen, Homburg, Ilsede
2026-10-01
Not yet open
IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE
NCT07521202HR+/HER2- Early Breast Cancer
Institut fuer Frauengesundheit
Not applicable
257
Erlangen
2026-10
Recruiting
Efficacy and Safety of SP16 in Preventing Acute Kidney Injury in At-risk Subjects With Chronic Kidney Disease Undergoing Elective Cardiac Surgery Using the Heart-lung-machine
NCT07661940AKI - Acute Kidney Injury
University of Erlangen-Nürnberg Medical School
Phase 2
120
Erlangen
2026-09-14
Not yet open
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors
NCT07762820Bladder Cancer, Bladder Cancer TNM Staging Primary Tumor (T) T1
Ludwig-Maximilians - University of Munich
Not applicable
75
Augsburg, Erlangen, Munich, Nuremberg
2026-09-01
Not yet open
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
NCT07603557Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
DrugsFludarabine Phosphate·Zola-cel·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
52
Magdeburg, Erlangen
2026-08-31
Recruiting
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
NCT05314998Pancreatic Ductal Adenocarcinoma
DrugsFolinic acid·Adrucil·Irinotecan·Capecitabine
John Neoptolemos
Phase 3
394
Aachen, Augsburg, Bochum, Bonn, Deggendorf, Dresden, Erlangen, Frankfurt
2026-08-17
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Aachen, Berlin, Cologne, Dresden, Erlangen, Essen, Hamburg, Hanover
2026-08-05
Not yet open
D-TECT: Pretreatment D-dimers and Disease Control in Advanced cSCC Treated With Cemiplimab
NCT07684066Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
Universitätsklinikum Hamburg-Eppendorf
Observational
116
Bielefeld, Bremerhaven, Buxtehude, Erlangen, Göttingen, Hamburg, Hanover, Kiel
2026-08-01
Recruiting
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
NCT07742735Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
DrugApraglutide
VectivBio AG
Phase 3
124
Heidelberg, Erlangen, Hamburg, Bonn, Essen, Münster, Aachen, Berlin
2026-08
Not yet open
Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)
NCT07553650Intracerebral Haemorrhage, Paediatric Stroke, Stroke Acute, Stroke
Charite University, Berlin, Germany
Observational
12,750
Hamburg, Berlin, Bielefeld, Dresden, Erlangen, Essen, Heidelberg, Leipzig
2026-07-27
Recruiting
Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
NCT07649681Multiple Myeloma (MM), GI Cancer, Taste Disorder, Melanoma (Skin Cancer)
Wuerzburg University Hospital
Not applicable
198
Augsburg, Erlangen, München, Regensburg, Würzburg
2026-07-24
Recruiting
More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
NCT07705178Acute Lymphatic Leukemia, Lymphoma
University of Erlangen-Nürnberg Medical School
Not applicable
180
Erlangen
2026-07-14
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
DrugsObrixtamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 3
390
Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hamburg
2026-07-10
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
900
Bad Oeynhausen, Berlin, Brandenburg an der Havel, Chemnitz, Duisburg, Erlangen, Frankfurt, Hamburg
2026-07-06
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213Type 2 Diabetes Mellitus
DrugsElecoglipron·Semaglutide
AstraZeneca
Phase 3
1,200
Bad Oeynhausen, Berlin, Chemnitz, Damme, Duisburg, Elsterwerda, Erlangen, Essen
2026-07-06
Recruiting
Pridopidine Phase 3 Study in Huntington's Disease
NCT07609108Huntington Disease
DrugPridopidine
Prilenia
Phase 3
400
Aachen, Bochum, Erlangen, Münster, Taufkirchen, Ulm
2026-07-01
Recruiting
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
NCT07647328ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Ribociclib
AstraZeneca
Phase 3
150
Berlin, Düsseldorf, Erlangen, Freiburg im Breisgau, Mönchengladbach, München, Paderborn, Trier
2026-06-15
Recruiting
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
NCT07519902Persistent Corneal Epithelial Defect
DrugCenegermin
Dompé Farmaceutici S.p.A
Phase 3
150
Erlangen, Frankfurt am Main, Marburg, Cologne, Düsseldorf, Homburg, Berlin
2026-06-02
Recruiting
Establishment and Evaluation of Standardized Clinical, Biological and Imaging Parameters to Assess the Response of LDRT in Heel Spur With Plantar Fasciitis
NCT06969820Calcaneal Spur
University of Erlangen-Nürnberg Medical School
Observational
35
Erlangen
2026-06-01
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugAsciminib single agent
Novartis Pharmaceuticals
Phase 2
50
Frankfurt am Main, Erlangen
2026-04-28
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
DrugsRisankizumab·Guselkumab
Janssen Research & Development, LLC
Phase 3
530
Berlin, Erlangen, Grevenbroich, Jena, Kiel, Ludwigshafen am Rhein, Mannheim, München
2026-04-21
Recruiting
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
NCT07788729Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer
University of Regensburg
Not applicable
384
Augsburg, Erlangen, Regensburg, Würzburg, Bayreuth, Berlin, Cologne
2026-04-21
Not yet open
Safety and Performance of a Pelvic Floor Mesh Implant for Laparoscopic Sacrocolpopexy (ProGYNious)
NCT07497321Pelvic Organ Prolapse (POP), Synthetic Mesh, Laparoscopic Surgery, Gynecologic Laparoscopic Surgery
A.M.I. Agency for Medical Innovations GmbH
Not applicable
100
Erlangen, Hausham, Frankfurt am Main
2026-04-15
Recruiting
Exploratory Investigation of the Acceptance and Utility of 14-day Trial Periods and Application-related Outcome Measurement (AbEM) Within the Routine Prescription of the DiGA Axia.
NCT07561255Spondylitis, Ankylosing, Mobile Phone Use
Wuerzburg University Hospital
Not applicable
200
Würzburg, Erlangen, Hamburg, Hattingen, Marburg, Nuremberg
2026-04-10
Recruiting
Controlling Hyperactive Immunity With Long-lived Lymphocytes
NCT07473154Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease
Quell Therapeutics Limited
Phase 1/2
16
Düsseldorf, Erlangen
2026-04-10
Recruiting
DEfeating PEnile CAncer-2
NCT07378670Penile Cancer, Penile Neoplasms Malignant
University Hospital Tuebingen
Not applicable
80
Berlin, Dresden, Erlangen, Mainz, Mannheim, München, Rostock, Tübingen
2026-04-10
Not yet open
BCC-One-Stop-Study
NCT07482956Basal Cell Carcinoma
University Hospital Augsburg
Not applicable
290
Augsburg, Dresden, Erlangen, Munich
2026-04-01
Recruiting
Improved Management of Patients With Recent-Onset Stable Chest Pain
NCT07476040Coronary Artery Disease (CAD)
Philipps University Marburg
Not applicable
3,369
Augsburg, Bad Neustadt an der Saale, Berlin, Cologne, Düsseldorf, Erlangen, Frankfurt, Giessen
2026-04-01
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 3
1,600
Bad Oeynhausen, Erlangen, Essen, Frankfurt, Gelnhausen, Hamburg, Hof, Köln - Dünnwald
2026-03-23
Recruiting
NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
NCT07424261Lupus Erythematosus, Systemic
AstraZeneca
Observational
125
Altenburg, Bad Bramstedt, Berlin, Braunschweig, Chemnitz, Erlangen, Heidelberg, Herne
2026-03-19
Recruiting
The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures
NCT07027306Osteoporotic Fractures, Osteoporosis
AO Foundation, AO Spine
Observational
648
Erlangen
2026-03-19
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Bad Oeynhausen, Erlangen, Essen, Frankfurt, Hamburg, Hof, Köln - Dünnwald, München
2026-03-16
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Augsburg, Erlangen, Koblenz, Ludwigshafen am Rhein, Magdeburg, Kiel, Jena, Berlin
2026-03-16
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 2
360
Freiburg im Breisgau, Mannheim, Tübingen, Ulm, Erlangen, Munich, Bochum, Düsseldorf
2026-03-10
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
DrugsDarzalex·Velcade·AZD0120·Carfilzomib
AstraZeneca
Phase 3
508
Berlin, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Mainz
2026-02-23
Recruiting
Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
NCT07531693HR+/HER2- Early Breast Cancer
Institut fuer Frauengesundheit
Observational
200
Erlangen
2026-02-19
Active, closed
WB-EMS Effects on Cardiometabolic Risk Factors
NCT07406191Hypertension, Metabolic Syndrome, Hypercholesterolemia, Hypertriglyceridemia
University of Erlangen-Nürnberg Medical School
Not applicable
28
Erlangen
2026-02-15
Recruiting
Lonely in Depression
NCT07333027Depression Disorder, Loneliness
Friedrich-Alexander-Universität Erlangen-Nürnberg
Observational
200
Erlangen
2026-02-05
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190Uveal Melanoma
DrugDarovasertib
IDEAYA Biosciences
Phase 3
520
Tübingen, Ulm, Erlangen, Essen, Dessau, Berlin, Bonn, Lübeck
2026-01-25
Recruiting
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT07266402Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
240
Augsburg, Berlin, Buxtehude, Darmstadt, Dresden, Düsseldorf, Erlangen, Göttingen
2026-01-15
Active, closed
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
NCT07352540Osteoarthritis, Knee
University of Erlangen-Nürnberg Medical School
Phase 2/3
46
Erlangen
2026-01-15
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1
27
Berlin, Erlangen, Hamburg, Jena, Mainz, Würzburg
2026-01-09
Recruiting
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
NCT07284433Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
DrugAllo-QuadCAR01-T
AvenCell Therapeutics, Inc.
Phase 1/2
178
Ulm, Erlangen, Munich, Marburg, Essen, Dresden, Berlin, Hamburg
2026-01-06
Recruiting
Effects of Dietary Supplementation With omega3-fatty Acids (Fish Oil) and Progressive Resistance Training on Skeletal Muscle Status in Gynaecological, Gastrointestinal and Urological Cancer Patients
NCT07643558Cancer Cachexia, Omega 3, Resistance Training, Cancer
University of Erlangen-Nürnberg Medical School
Not applicable
288
Erlangen
2026-01-01
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
DrugsFolfiri·Pumitamig·Folfox·Bevacizumab
Bristol-Myers Squibb
Phase 2/3
990
Erlangen, Hanover, Dresden, Berlin, Bochum, Chemnitz, Düsseldorf, Frankfurt
2025-12-31
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
DrugsTersolisib·Exemestane·Anastrozole·Ribociclib
Eli Lilly and Company
Phase 3
800
Berlin, Bottrop, Cologne, Dessau, Donauwörth, Dresden, Düsseldorf, Erlangen
2025-12-22
Recruiting
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
NCT07314164Neuroendocrine Tumors
Ipsen
Observational
150
Aschaffenburg, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Erlangen
2025-12-17
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Bad Saarow, Bielefeld, Bonn, Cologne, Dresden, Duisburg, Düsseldorf, Erlangen
2025-12-12
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Münster, Mainz, Berlin, Dresden, Erlangen
2025-12-03
Recruiting
OCTA in Cardiovascular Disease and Healthy Controls
NCT07359664Patients With Cardiovascular Disease, Healthy Participants
University of Erlangen-Nürnberg Medical School
Not applicable
64
Erlangen
2025-12-01
Recruiting
Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy
NCT07131956Prostate Cancer (Diagnosis), Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer Recurrent
University of Erlangen-Nürnberg Medical School
Observational
200
Augsburg, Erlangen, Munich
2025-12
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel
Amgen
Phase 3
750
Berlin, Bonn, Dresden, Erlangen, Essen, Hamburg, Heidelberg, Jena
2025-11-28
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Beelitz, Berlin, Bochum, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hanover
2025-11-24
Recruiting
Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy
NCT07313878Acute Lymphoblastic Leukaemias (ALL), Long Term Follow-Up
University of Erlangen-Nürnberg Medical School
Not applicable
30
Erlangen
2025-11-19
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Erlangen, Göttingen, Cologne, Berlin
2025-11-19
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811NonSegmental Vitiligo
DrugRuxolitinib
Incyte Corporation
Phase 3
250
Berlin, Erlangen, Hamburg, Kiel, Leipzig, Mainz, München, Münster
2025-11-13
Active, closed
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,060
Erlangen, Berlin, Bonn, Cologne, Dresden, Homburg/Saar, Jena, Leipzig
2025-11-12
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Berlin, Dachau, Erlangen, Regensburg, Ulm
2025-11-10
Recruiting
Evaluating the Effectiveness of Typology-based Coaching on Patients' Therapy Management
NCT07708571HR+/HER2- Early Breast Cancer
Institut fuer Frauengesundheit
Not applicable
548
Augsburg, Erlangen, Hösbach
2025-11-04
Recruiting
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
Universität Münster
Phase 2
120
Aachen, Augsburg, Berlin, Bielefeld, Chemnitz, Düsseldorf, Erlangen, Essen
2025-10-31
Recruiting
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
NCT07026474Recurrent Head and Neck Squamous Cell Carcinoma
DrugsAdrucil·Cisplatin·Pembrolizumab
Universität des Saarlandes
Phase 3
214
Berlin, Chemnitz, Darmstadt, Dresden, Erfurt, Erlangen, Frankfurt am Main, Giessen
2025-10-30
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
DrugsMIRV·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Eli Lilly and Company
Phase 3
1,630
Aachen, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Essen
2025-10-22
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Berlin, Dachau, Erlangen, Halle, Hanover, Jerichow, Kiel, Leipzig
2025-10-03
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Aachen, Berlin, Dachau, Erlangen, Halle, Hanover, Jerichow, Kiel
2025-10-01
Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
NCT07041099Sjögren, Sjogren Disease, Sjogren's Syndrome
DrugCLN-978
Cullinan Therapeutics Inc.
Phase 1
36
Erlangen, Hanover
2025-10-01
Recruiting
Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers
NCT06855134Rare Cancer
German Cancer Research Center
Observational
946
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2025-09-29
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
DrugRilzabrutinib
Sanofi
Phase 3
124
Berlin, Erlangen, Hanover, Minden, Ulm
2025-09-26
Recruiting
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
NCT07115953Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
130
Homburg, Lübeck, Erlangen, Leipzig, Villingen-Schwenningen
2025-09-22
Recruiting
Characterization of Renal Microvascular Alterations in Patients With Active Urinary Sediment and/or Proteinuria Using Ultrasound Localization Microscopy
NCT07469059Nephritis
University of Erlangen-Nürnberg Medical School
Observational
30
Erlangen
2025-09-18
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
DrugsCapivasertib·Fulvestrant
Relay Therapeutics, Inc.
Phase 3
540
Aschaffenburg, Bottrop, Dresden, Eggenfelden, Erlangen, Freiburg im Breisgau, Krefeld, Mannheim
2025-08-26
Recruiting
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
NCT06988618Prurigo Nodularis
Galderma R&D
Observational
600
Karlsruhe, Erlangen, Rostock, Kiel, Ahaus, Berlin, Bielefeld, Haslach
2025-08-11
Recruiting
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
NCT06981325Basal Cell Carcinoma (BCC), First Line Treatment
DrugCemiplimab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
34
Erfurt, Erlangen, Heidelberg, Leipzig, Minden, Oberhausen, Tübingen
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Erlangen, Essen, München
2025-08-06
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
DrugsPF-07248144·Exemestane·Everolimus·Fulvestrant
Pfizer
Phase 3
400
Ulm, Erlangen, Berlin, Hamburg
2025-08-05
Not yet open
Diagnostic Imaging of Vascular Malformations Using MSOT and ULM
NCT06994260Vascular Malformation, Arteriovenous Malformation, Lymphatic Malformation, Venous Malformations
University Hospital Erlangen
Observational
15
Erlangen
2025-08-01
Recruiting
Real World Data Collection on the INSPIRIS RESILIA Aortic Valve
NCT07120048Aortic Valve Disease
Edwards Lifesciences
Observational
500
Heidelberg, Bad Neustadt an der Saale, Erlangen, Munich, Passau, Oldenburg, Bad Oeynhausen, Wuppertal
2025-07-30
Recruiting
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)
NCT07047703Axial Spondyloarthritis (AxSpA)
Grey Wolf Therapeutics
Phase 1/2
140
Bochum, Erlangen
2025-07-28
Recruiting
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244Acute Ischemic Stroke, Cerebral Stroke
DrugSovateltide
Pharmazz, Inc.
Phase 3
514
Altenburg, Göttingen, Rhein, Minden, Recklinghausen, Berlin, Bad Neustadt an der Saale, Erlangen
2025-07-24
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Berlin, Erlangen, Essen, Mainz, Marburg, Tübingen, Würzburg
2025-07-21
Recruiting
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
NCT06988605Atopic Dermatitis
Galderma R&D
Observational
1,000
Karlsruhe, Langenau, Augsburg, Erlangen, Regensburg, Remscheid, Ahaus, Berlin
2025-07-14
Active, closed
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis
DrugsZola-cel·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Leipzig, Magdeburg, Berlin, Cologne, Erlangen, Herne
2025-07-14
Recruiting
Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)
NCT07067437Breast Neoplasms
National Institute of Oncology, Hungary
Not applicable
250
Bremerhaven, Erlangen, Lübeck, Offenbach, Würzburg
2025-07-01
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Sacituzumab tirumotecan·Olaparib·Doxorubicin
Merck Sharp & Dohme LLC
Phase 3
2,400
Erlangen, Munich, Paderborn, Koblenz, Saarbrücken, Berlin
2025-06-30
Active, closed
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 3
580
Berlin, Bochum, Darmstadt, Dresden, Erlangen, Hamburg, Lübeck
2025-06-23
Recruiting
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
NCT06717958AML, MDS
DrugIvosidenib
Technische Universität Dresden
Phase 2
76
Aachen, Chemnitz, Dresden, Erlangen, Essen, Frankfurt am Main, Greifswald, Halle
2025-06-17
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
DrugsRisankizumab·Vedolizumab
AbbVie
Phase 3
573
Freiburg im Breisgau, Ulm, Dachau, Erlangen, Regensburg, Frankfurt am Main, Essen, Minden
2025-06-17
Active, closed
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 3
9
Aachen, Berlin, Cologne, Dresden, Erlangen, Frankfurt am Main, Freiburg im Breisgau, Göttingen
2025-06-04
Recruiting
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT06568627Venous Leg Ulcer (VLU)
DrugEscharEx
MediWound Ltd
Phase 3
216
München, Chemnitz, Berlin, Bochum, Dresden, Erlangen, Kiel
2025-06-01
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Erlangen, Essen, München
2025-05-30
Recruiting
Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy
NCT07021820Centronuclear Myopathy
University of Erlangen-Nürnberg Medical School
Observational
40
Erlangen
2025-05-29
Recruiting
A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
NCT06695897Eosinophilic Esophagitis
DrugDupilumab
Sanofi
Observational
150
Aschaffenburg, Augsburg, Dachau, Erlangen, Giessen, Wetzlar, Osnabrück, Weyhe-Kirchweyhe
2025-05-28
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
450
Berlin, Erlangen, Lübeck, Mainz Am Rhein, Münster
2025-05-19
Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
NCT06994143Rheumatoid Arthritis (RA
DrugCLN-978
Cullinan Therapeutics Inc.
Phase 1
37
Erlangen, Heidelberg
2025-05-19
Recruiting
Ultrasound Localization Microscopy in Patient With Congenital Anomalies of the Kidney and Urinary Tract (CAKUT)
NCT06921733Congenital Anomalies of Kidney and Urinary Tract, Lower Urinary Tract Obstruction, Congenital, Ureteropelvic Junction Obstruction, Hydronephrosis Congenital
University of Erlangen-Nürnberg Medical School
Observational
20
Erlangen
2025-05-13
Recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07227246Intracerebral Hemorrhage
DrugRecombinant Factor VIIa
Joseph Broderick, MD
Phase 3
350
Heidelberg, Erlangen, Frankfurt am Main, Augsburg, Berlin, Hamburg, Tübingen
2025-05-06
Recruiting
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
NCT06916507Parkinson's Disease
AbbVie
Observational
125
Allensbach, Heidelberg, Tübingen, Ulm, Wolfach, Erlangen, Ingolstadt, Munich
2025-05-06
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD5492
AstraZeneca
Phase 1
72
Cologne, Erlangen, Magdeburg
2025-05-01
Recruiting
Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel
NCT06947668Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of the Hypopharynx, Larynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
University of Erlangen-Nürnberg Medical School
Observational
250
Erlangen
2025-05-01
Rows per page Showing 1–100 of 362
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-germany/city/erlangen

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 362 of those studies with a site in Erlangen.

How many clinical trials are recruiting in Erlangen?

207 of the 362 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 11 have not yet opened recruitment, 137 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Erlangen), 362 studies
PhaseStudiesRecruitingShare
Phase 31456040.1%
Observational735520.2%
Not applicable533914.6%
Phase 2432111.9%
Phase 1/217144.7%
Phase 11574.1%
Phase 2/31283.3%
Phase 4431.1%

Most active sponsors

Lead sponsors with the most studies (Erlangen)
Lead sponsorStudiesRecruiting
University of Erlangen-Nürnberg Medical School4136
AstraZeneca2611
AbbVie174
Hoffmann-La Roche126
Merck Sharp & Dohme LLC127
Eli Lilly and Company107
Janssen Research & Development, LLC103
Novartis Pharmaceuticals105
Bristol-Myers Squibb95
Boehringer Ingelheim64
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.